App-based education for taking apixaban with atrial fibrillation
Part of Heart & circulation clinical trials.
This study tests whether a smartphone app that teaches patients about their blood thinner (apixaban, also called Eliquis) helps them take it more regularly. If you have atrial fibrillation and take apixaban, this app might help you manage your medication better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 19 years or older
- You have atrial fibrillation (irregular heartbeat) that is not caused by a heart valve problem
- You are currently taking the blood thinner apixaban (also called Eliquis)
- You are willing to use a mobile app on your smartphone or tablet
- You are able to understand the study and give your consent
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a 'pill-in-the-pocket' approach for blood thinners after a catheter ablation for atrial fibrillation. Instead of taking a daily blood thinner, you may only take it when needed, which could reduce the risk of bleeding while still preventing strokes.
This study compares two blood-thinning medicines, edoxaban and apixaban, to see which one is better at preventing strokes and bleeding in people who have both atrial fibrillation and coronary artery disease. If you're eligible, you may receive one of these standard treatments, and the trial could help find the safer option.
This study tests whether a smartphone app can help people recover after a new type of heart ablation called pulse field ablation for atrial fibrillation. It aims to see if the app improves follow-up care and quality of life.
This trial tests whether apixaban, a blood thinner, works well for people with atrial fibrillation who also have heart or circulation conditions. It uses a smartphone app to help track your treatment.
This trial tests how well patients with atrial fibrillation take their apixaban medication and whether it is safe. It aims to see if using apixaban for the first time works well without causing bleeding problems.
This trial tests apixaban (a blood thinner) to prevent stroke in people with atrial fibrillation or atrial flutter who have very poor kidney function or are on dialysis. If you qualify, you may help researchers find a safer way to lower stroke risk for this higher-risk group.
Hear when a new Atrial Fibrillation on Apixaban Treatment trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.